Overview

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Status:
Completed

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the safety and tolerability of sequential atezolizumab followed by sipuleucel-T (Arm 1) vs. sipuleucel-T followed by atezolizumab (Arm 2) in patients who have asymptomatic or minimally symptomatic metastatic CRPC, not previously treated with docetaxel or cabazitaxel.

Phase:

Phase 1

Details

Lead Sponsor:

University of Hawaii

Collaborators:

Dendreon
Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab